APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

January 6, 2021
Appili Therapeutics to Present at the 2021 VIRTUAL H.C. Wainwright BioConnect Conference
December 22, 2020
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (Favipiravir) Tablets for the Treatment of COVID-19 Under Health Canada’s Interim Order
December 2, 2020
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States
November 24, 2020
Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets (Favipiravir) in the Prevention of COVID-19 in Exposed Individuals in the Community